

## Minimal/measurable residual disease in AML:

Schuurhuis, Gerrit J; Heuser, Michael; Freeman, Sylvie; Béné, Marie-Christine; Buccisano, Francesco; Cloos, Jacqueline; Grimwade, David; Haferlach, Torsten; Hills, Robert K; Hourigan, Christopher S; Jorgensen, Jeffrey L; Kern, Wolfgang; Lacombe, Francis; Maurillo, Luca; Preudhomme, Claude; van der Reijden, Bert A; Thiede, Christian; Venditti, Adriano; Vyas, Paresh; Wood, Brent L

DOI:

[10.1182/blood-2017-09-801498](https://doi.org/10.1182/blood-2017-09-801498)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Schuurhuis, GJ, Heuser, M, Freeman, S, Béné, M-C, Buccisano, F, Cloos, J, Grimwade, D, Haferlach, T, Hills, RK, Hourigan, CS, Jorgensen, JL, Kern, W, Lacombe, F, Maurillo, L, Preudhomme, C, van der Reijden, BA, Thiede, C, Venditti, A, Vyas, P, Wood, BL, Walter, RB, Döhner, K, Roboz, GJ & Ossenkoppele, GJ 2018, 'Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party', *Blood*. <https://doi.org/10.1182/blood-2017-09-801498>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

This research was originally published in Blood. Gerrit J. Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K. Hills, Christopher S. Hourigan, Jeffrey L. Jorgensen, Wolfgang Kern, Francis Lacombe, Luca Maurillo, Claude Preudhomme, Bert A. van der Reijden, Christian Thiede, Adriano Venditti, Paresh Vyas, Brent L. Wood, Roland B. Walter, Konstanze Döhner, Gail J. Roboz and Gert J. Ossenkoppele. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018 © the American Society of Hematology.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# **Minimal/Measurable Residual Disease in AML: Consensus Document from ELN MRD Working Party. A tribute to David Grimwade**

Gerrit J Schuurhuis<sup>1</sup>, Michael Heuser,<sup>2</sup> Sylvie Freeman<sup>3</sup>, Marie-Christine Béné<sup>4</sup>, Francesco Buccisano<sup>5</sup>, Jacqueline Cloos<sup>1,6</sup>, David Grimwade<sup>7</sup>, Torsten Haferlach<sup>8</sup>, Robert K Hills<sup>9</sup>, Christopher S Hourigan<sup>10</sup>, Jeffrey L Jorgensen<sup>11</sup>, Wolfgang Kern<sup>8</sup>, Francis Lacombe<sup>12</sup>, Luca Maurillo<sup>5</sup>, Claude Preudhomme<sup>13</sup>, Bert A van der Reijden<sup>14</sup>, Christian Thiede<sup>15</sup>, Adriano Venditti<sup>5</sup>, Paresh Vyas<sup>16</sup>, Brent L Wood<sup>17,18</sup>, Roland B Walter<sup>17,18</sup>, Konstanze Döhner<sup>19</sup>, Gail J Roboz<sup>20</sup> and Gert J Ossenkoppele<sup>1</sup>

<sup>1</sup>Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

<sup>2</sup>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

<sup>3</sup>Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK

<sup>4</sup>Hematology Biology, University Hospital Nantes, Nantes, France

<sup>5</sup>Department of Biomedicine and Prevention, University of Rome, Tor Vergata, Rome, Italy

<sup>6</sup>Department of Pediatric Oncology, VU University Medical Center, Amsterdam, Netherlands

<sup>7</sup>Division of Genetics & Molecular Medicine, King's College, London, UK

<sup>8</sup>Munich Leukemia Laboratory, Munich, Germany

<sup>9</sup>Centre for Trials Research, Cardiff University, Cardiff, UK

<sup>10</sup>Myeloid Malignancies Section, National Institutes of Health, Bethesda, USA

<sup>11</sup>Division Pathology/Lab Medicine, Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas, USA

<sup>12</sup>Flow cytometry Platform, University Hospital, Bordeaux, France

<sup>13</sup>Center of Pathology, Laboratory of Hematology, University Hospital of Lille, Lille, France

<sup>14</sup>Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, Netherlands.

<sup>15</sup>Universitätsklinikum Carl Gustav Garus an der Technischen Universität Dresden,  
Dresden, Germany

<sup>16</sup>MRC Molecular Haematology Unit, Oxford Centre for Haematology, University of  
Oxford and Oxford University Hospitals NHS Trust Oxford OX3 9DS, Oxford, UK

<sup>17</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA;

<sup>18</sup>University of Washington, Seattle, WA, USA

<sup>19</sup>Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

<sup>20</sup>Weill Cornell Medicine and The New York Presbyterian Hospital, New York, USA

Running head: SCHUURHUIS et al. ELN CONSENSUS DOCUMENT ON MRD IN AML

Journal section designation: PLENARY PAPER

Scientific section designation: MYELOID NEOPLASIA

M.H. and S.F. contributed equally to this study

K.D. and G.J.R. contributed equally to this study

Word count: 6502

Abstract word count: 196

Correspondence to:

Gerrit J Schuurhuis

Department of Hematology

VU University Medical Center

Amsterdam, Netherlands

Email: [gj.schuurhuis@vumc.nl](mailto:gj.schuurhuis@vumc.nl)

Tel: +31 235636488

+31 204442497

## **Abstract**

Measurable residual disease (MRD, previously termed minimal residual disease) is an independent, post-diagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multi-parameter flow cytometry (MFC) and molecular protocols but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over two years, during four meetings by a specially designated MRD working party of the European LeukemiaNet (ELN). The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the USA. The manuscript is dedicated to the memory of our esteemed colleague David Grimwade, a pioneer in the field of MRD in AML, and an active participant in the present work.

## Introduction

A myriad of factors present at diagnosis in acute myeloid leukemia (AML), including cytogenetics, molecular genetics, and age have been associated with prognosis, but still fall short in accurately predicting outcomes<sup>1-3</sup> Increasing evidence now indicates that the ability to identify residual disease far below the morphology-based 5% blast threshold is an important tool for refining our approach to risk classification. Minimal or, more appropriately, measurable residual disease (MRD) denotes the presence of leukemia cells down to levels of 1:10<sup>4</sup> to 1:10<sup>6</sup> white blood cells, compared to 1:20 in morphology-based assessments. There are several reasons to apply MRD detection in AML: 1) to provide an objective methodology to establish a deeper remission status, 2) to refine outcome prediction and inform post-remission treatment, 3) to identify impending relapse and enable early intervention, 4) to allow more robust post-transplant surveillance, and 5) to use as a surrogate endpoint to accelerate drug testing and approval.

Numerous studies have investigated the value of MRD in AML and have consistently shown that MRD negativity, as defined by specified cut-off values, is highly prognostic for outcome (see e.g. Table 1 for flowcytometric MRD). Reflecting the molecular diversity of AML, different MRD platforms are available for detecting MRD. Two methods are currently widely applied: multiparameter flow cytometry (MFC) and real-time quantitative polymerase chain reaction (RQ-PCR), while newer technologies, including digital PCR and Next Generation Sequencing (NGS), are emerging. Each methodology differs in the proportion of patients to whom it can be applied and in its sensitivity to detect MRD. It is expected that integration of baseline factors and assessment of MRD will improve risk assessment.<sup>4</sup> MRD assessments are performed in an increasing number of laboratories worldwide and used in various clinical settings. However, no guidelines or recommendations are available on how and when to apply MRD assessments, and how to translate the results to clinical practice. An international group of experts addressed these issues on behalf of the European LeukemiaNet (ELN) and reports here on its conclusions.

## Methods

An international panel of 24 experts, including 19 from European countries and 5 from the United States, met four times during 2016 and 2017, with numerous email

exchanges during this time. The panel included members with recognized technical, clinical, and translational knowledge of MRD in AML, including specific expertise on MFC MRD, molecular MRD, NGS, and clinical issues. For the clinical section, only MRD publications including at least 50 patients were reviewed (Table 1). Unpublished technical details from individual laboratory directors were also discussed and used. In several areas, there was inadequate data to draw firm conclusions. The final ELN MRD recommendations are subdivided in three parts: MFC, molecular, and clinical. The paper presents a summary of consensus and non-consensus issues, with extended views present in Supplementary text under headings corresponding to those in the main document.

## **Flowcytometric (MFC) MRD**

### **Approaches for MFC MRD assessment (LAIP versus different-from-normal)**

For the detection of MRD, a comprehensive panel characterized by early marker(s) like CD34 and CD117, myeloid-lineage associated markers, and differentiation antigens like CD2, CD7, CD19 or CD56, must track aberrant AML blast cells.

Two separate approaches have been used for assessing MFC MRD: 1) the LAIP approach, which defines Leukemia Associated Immunophenotypes at diagnosis and tracks these in subsequent samples; 2) the Different-from-Normal (DfN) approach that is based on the identification of aberrant differentiation/maturation profiles at follow up. The DfN approach can be applied if information from diagnosis is not available, and also to detect new aberrancies, together with disappearance of diagnosis aberrancies, referred to in earlier literature as “immunophenotype shifts”<sup>5-7</sup> These may emerge from leukemia evolution or clonal selection.<sup>8,9,10</sup> In essence, LAIPs are DfN abnormalities in the vast majority of cases, and the difference between these two approaches is likely to disappear if an adapted, sufficiently large panel of antibodies (preferably  $\geq 8$  colors) is utilized.

We recommend that the advantages of both approaches be combined to best define MFC MRD burden, allowing detection of new aberrancies emerging at follow-up and monitor patients when there is an absence of diagnostic information.

The ELN MRD working party suggests the term ‘LAIP-based DfN approach’ for this combined strategy. To be more specific, aberrancies may be referred to as LAIPs or DfN-

LAIP, whichever is the more appropriate term. LAIPs and DfN-LAIPs can be further categorized as 1) diagnostic, 2) follow-up (based on diagnosis information), 3) follow-up (no diagnostic information) 4) changed (i.e. new aberrancy compared to diagnosis LAIPs or previous follow-up LAIPs).

*Suggestion for further improvements:*

We recommend to use the integrated LAIP-based DfN approach to separately validate the, largely unknown, prognostic impact of emerging aberrancies.

### **Markers for MRD assessment**

*Marker Panel content.* Many different panels of markers have been used to assess MRD (for the panels currently used by the ELN Working Group members, see Suppl. Table 1). Based on the collective experiences of the working group, a two-step consensus recommendation is proposed, that includes gating on CD45, sideward scatter (SSC), forward scatter (FSC), a primitive marker (CD34, CD117), and abnormal expression of marker(s) or abnormal combination(s) of marker expression. In addition, a monocytic combination, including CD64, CD11b and CD4 (see legends of Suppl. Table 1), is proposed to assess MRD in monocytic or myelomonocytic AML.<sup>11,12</sup> Other interesting markers are in Suppl. Table 1, and include CD133, CD38 and CD123 that allow to define more primitive progenitor and/or leukemia stem cell populations.<sup>13,14</sup>

*Number and nature of fluorochromes.* We recommend using a minimum of eight colors. Although not formally proven, this may allow more specific assessment of aberrancies than is feasible with fewer colors.

Rather than recommending suitable clones and fluorochromes, the panelists suggest taking advantage of extensive validation studies as done, for example, by the Euroflow consortium<sup>15</sup> and the French GEIL group (consensus document in revision). Specific attention should be given to Staining Index of fluorochromes (see Suppl. text).

Using the same tubes (with the same antibody-fluorochrome combinations) at diagnosis and at follow-up is considered a prerequisite for the LAIP-based DfN approach of tracking of both LAIPs established at diagnosis and emerging aberrancies.

*Suggestions for further improvements:*

1. To minimize the number of different panels used, we strongly recommend the design and validation of a single common panel-assay, preferably as an ELN initiative, for all MRD studies.<sup>16</sup>
2. We recommend exploration of the value of a separate (single tube) LSC panel (see Suppl. Figure 1) in which the total LSC load can be assessed at any time from diagnosis to relapse.<sup>17</sup> Validation of such a panel has been initiated amongst different ELN and non-ELN members.

**Technical requirements**

*Bone marrow sampling.* Sampling for MFC MRD usually is done in such anti-coagulants as EDTA or heparin, with no significant difference between these. A recurrent concern is that MFC MRD in peripheral blood (PB) is characterized by a lower frequency than in BM (up to approximately 1 log.<sup>18,19</sup>). The use of PB at present cannot be recommended.<sup>20</sup> To maximize assay sensitivity, it is mandatory to avoid hemodilution of BM samples. We therefore strongly recommend to submit the first BM pull for MRD analysis, at least for follow up BM samples intended for MFC MRD, preferably using the same volume across time points and patients. It is recommended to estimate the possible contamination with PB, the presence of more than 90% mature neutrophils in a BM sample indicating significant hemodilution.<sup>20-24</sup> Sampling time points and volumes for MFC (and molecular) assays are outlined in Suppl. Table 2.

*Bone marrow transport.* In the multicenter setting, we recommend transport at controlled room temperature. Up to three days storage is allowed, without the need for a viability marker, provided BM is stored undiluted.

*Flow cytometers.* Basic principles of flow cytometric settings have been described for many purposes including MRD.<sup>25-27</sup> Harmonization of instrument settings is of high value for inter-laboratory comparison of results. One robust, simple way to assess this harmonization has been described by the Harmonemia study.<sup>27</sup> The Euroflow consortium also provided standard operating procedures for their panels.<sup>25</sup>



*Preparation of samples.* There are two major approaches for preparing BM samples for FCM: 1) stain/lyse/wash (or no wash), has the advantage of reducing cell losses; 2) bulk lysis followed by washing, staining (and washing) has the advantage of having all tubes prepared in a similar way for the different staining steps. Both approaches are in use for AML MRD assays. Incubation typically should be performed in the dark to preserve the quality of fluorochromes. The greater skill, with no consensus at the moment, resides in the analysis step, typically using a series of linked gatings aiming at best identifying the MRD population. Comparison with the diagnosis pattern is the safest, seeking for residual cells of the same population as that seen at diagnosis. However, in some instances, a clearly focused population, differing from the initial one, can be seen. It may represent a shift of the initial clone/population or the emergence of a chemotherapy-resistant sub-population. Whether this will lead to relapse is impossible to determine, but it is recommended that in such instances closer surveillance of the patient is suggested.

#### **How to calculate MRD burden and minimal requirements**

Several strategies have been used to quantify the MRD burden. To harmonize reporting we recommend the following.

- 1) Use LAIPs that clearly occupy an empty space, ie aberrancies not found at the same MFC location in control BM, at diagnosis and follow up. In cases where only part of a population is occupying an empty space, inclusion of additional cells outside the empty space is allowed provided they define one single clustered population together with the cells from the empty space.
- 2) Use the best (most specific and/or highest frequency) LAIP for assessing MRD frequency; in case of multiple, non-overlapping LAIPs, frequencies of individual LAIPs should be added up.
- 3) Relate LAIP events to the leukocyte population of CD45<sup>+</sup> cells (excluding CD45<sup>+</sup> erythroblasts).
- 4) Use the diagnosis LAIPs if diagnosis sample and diagnosis LAIPs are available to optimally inform MRD gating for these LAIPs.
- 5) Use the DfN approach to identify any new LAIPs. Such new LAIPs can be used for quantitation.

It is also recommended to acquire between 500,000-1 million events (excluding all CD45<sup>-</sup> negative cells and debris) unless the cluster of MRD becomes obvious during acquisition and is recognized by a trained operator.

*Suggestion for further improvements:*

In order to minimize subjectivity in data-interpretation/-analysis, it is recommended to evaluate the possibilities for improved discrimination of LAIPs achieved by multiparameter displays, such as principal component analysis (PCA) in commercially available programs, e.g. in the APS system of the Kaluza<sup>®</sup> or Infinicyte<sup>®</sup> programs. Several initiatives are ongoing to develop and/or apply more sophisticated analysis programs.

**Thresholds and time points for MRD assessment during treatment**

The present concept is to use MRD for risk analysis at an early time point prior to consolidation therapy. With the large number of aberrancies that can be defined (up to one hundred<sup>28</sup> and their inherent differences in specificity, cut-off levels that capture MRD positivity applicable to *all* LAIPs, have to be relatively high, ie 0.035% to 0.2% (Table 1, and Table 2 in Ossenkoppele and Schuurhuis<sup>29</sup>). A cut-off of 0.1% was included and found relevant in most published studies to date and, thus, we recommend using 0.1% as the threshold to distinguish MRD-positive from MRD-“negative” patients. However, it should be noted that MRD tests with MRD quantified below <0.1% may still be consistent with residual leukemia, and several studies have shown prognostic significance of MRD levels below 0.1%.<sup>12,29-32</sup> Thus cut-off levels below 0.1% e.g. <0.01% may define patients with particularly good outcome.

*Suggestion for further improvements:*

To perform retrospective analyses for patients with MRD burden <0.1% but >0% versus ≥0.1%.

**Thresholds and time points for MRD assessment during follow up/definition of relapse**

In general, the definition of MRD positivity after consolidation therapy is similar to the post-induction definition.<sup>33</sup> Not much is known about the optimal time intervals for

clinically relevant sequential measurements of MRD.<sup>34</sup> More information on such time intervals is reported in molecular MRD studies (see below).

*Suggestion for further improvements:*

With the emergence of potential novel remission treatment options in AML, there is urgent clinical need to establish the optimal intervals needed to define progression/impending relapse. Unpublished data from several institutions exist on sequential MRD measurements, and may be informative.

**Design of MRD studies: multicenter versus single center approaches**

To facilitate and optimize data from MRD studies, we recommend that for *multicenter studies* samples may be processed by different centers applying the same MRD panels, according to the recommendations offered in the present paper. With insufficient experience in MRD analysis, the final interpretation should be performed at a central institute or in a group workshop. Alternatively, samples may be sent under carefully controlled conditions (see Technical requirements) to a central institute for work-up and analysis. The advantages of such centralized approach need to be weighed against the disadvantages, for example delays in processing and/or in establishing a final report for clinical decision making. For *single center* studies in institutions with relevant experience, we recommend following the procedures described in this paper. *Single center* studies without relevant experience are strongly discouraged. The present local policies of the ELN Working Group members are outlined in Suppl. Table 3.

*Suggestion for further improvements:*

With the increasing number of centers embarking on MRD studies, it is strongly recommended to establish working relationships with experienced centers. Meanwhile, we hope, and will support, that community practices and commercial laboratories seek opportunities to design common panels and procedures.

**How to report MRD**

In general, the minimum number of cells needed for accurate reporting of MRD is 500,000-1 million, excluding all CD45-negative cells and debris, although lower cell numbers may still suffice if the level of MRD is relatively high, and notably to merely

assess a positive/negative status based on the 0.1% ( $10^{-3}$ ) threshold. The high numbers enable to assess possible MRD below the level of 0.1% (see below: point 4).

Reports on MRD status should be constructed to allow the clinicians to draw clear conclusions about how to interpret the report. Elements in an MRD report should contain the following parameters (see also Figure 1A &B):

1. A) Absolute numbers of LAIP and WBC, and LAIP cells as percentage of WBC; B) For diagnostic LAIPs, the percentage coverage of blast cells at diagnosis; C) Clinicians and laboratory staff should collaborate to decide if the final report will contain a statement “MRD-positive” or “MRD-negative” (ie MRD  $\geq 0.1\%$  or  $< 0.1\%$ ). In cases with complete absence of aberrancies, the term “no MFC MRD identified” can be added to report of “MRD negative”.

2. Detection sensitivity threshold for the aberrancy used with details: all aberrancies have the 0.1% threshold level, but additional information about the particular nature (sensitivity/specificity) of an aberrancy may be important, for example nature of myeloid, primitive, aberrant and exclusion marker, especially in cases of newly defined LAIPs not present at diagnosis.

3. Comments on quality of the sample, for example viability, insufficient regeneration, PB contamination (Figure 1B). For suboptimal samples with detectable MRD, numbers of LAIP<sup>+</sup> cells need to be communicated.

4. It is up to the clinician (or clinical study group) how to deal with information for MRD  $< 0.1\%$ : the report could contain “MRD detectable but  $< 0.1\%$ , may be consistent with residual leukemia” but also the statement “this level has not been clinically validated” when applicable for the laboratory involved. Alternatively, MRD  $< 0.1\%$  may be reported as “MFC MRD detectable and quantifiable, but with uncertain significance”. Leaving out such information may have medico-legal consequences.

An example of a report form is shown in Figure 1B.

#### *Suggestion for further improvements:*

As outlined earlier, very low levels of MRD ( $< 0.01\%$ ) differentiate patients with a particularly good prognosis in some studies. Meta-analysis of prognostic models from other study groups, as well as independent validation of these very low threshold levels, may be of clinical importance.

## **Future directions**

Retrospective analyses of databases to establish the value of the DfN versus LAIP approach in terms of prognostic impact, further exploration of the value of LSC detection in prognosis and the urgent need for testing automated data analysis programs, are of great importance in future studies of MRD in AML.

Optimizing the use of PB for MRD analysis, if feasible, would reduce the need for painful, time-consuming, and expensive BM testing.<sup>18,19</sup> For the moment, PB MRD may offer a “first indication”, but BM MRD should always be assessed to define the MRD status of the patient (“positive” or “negative”).

As a final area of investigation, in contrast to molecular MRD, nothing is known about the possible relationship between pre-leukemic populations and immunophenotypic aberrancies. Investigation of this potential relationship may become important in the future.

## **Molecular MRD**

### **Approaches for molecular MRD assessment**

There are two general approaches to molecular MRD assessment: real-time PCR-based approaches, and sequencing approaches wherein sequences from individual DNA/cDNA molecules are generated.

The PCR approach includes classical quantitative real time PCR (qPCR) using fluorescent probes, digital PCR, and molecular chimerism analysis.<sup>35</sup> This approach is usually of high sensitivity and therefore currently considered the gold standard. However, its applicability is limited to the approximately 40% of AML patients that harbor one or more suitable abnormalities.

Next generation sequencing for MRD assessment can, theoretically, be applied to all leukemia specific genetic aberrations. With improved experimental and bioinformatics approaches, we expect this approach to become applicable for another 40-50% of AML patients.

In general, we suggest that a MRD platform should be able to detect leukemic cells to a level of 0.1% (1 in 1000 mutated cells). We recommend the use of real time qPCR platforms for MRD assessment due to their established high sensitivity. In the future, it

is likely that NGS and digital PCR platforms will be used after careful validation. Genescan-based fragment analysis (e.g for FLT3 aberrations) has a low priority as a MRD platform due to limited sensitivity.

### **Markers for molecular MRD assessment**

The persistent presence of *NPM1* mutations and the fusion genes *RUNX1-RUNX1T1*, *CBFB-MYH11* and *PML-RARA* following therapy is a strong predictor of relapse. Thus, patients with these abnormalities should have molecular assessment of residual disease using qPCR (sensitivity  $10^{-4}$  to  $10^{-6}$ ) at informative clinical time points (see below).

Pre-leukemic founder clones (and associated mutations; typical examples are those observed for *DNMT3A*, *ASXL1* and *TET2* genes) may persist at significant levels, even upon achievement of complete morphological remission,<sup>36-38</sup> but the detection of these may not reliably represent the presence of AML MRD and may not be of prognostic significance. Mutations in these genes also occur in healthy individuals with increasing frequency as they age.<sup>39,40,41</sup> This is referred to as age-related clonal hematopoiesis (ARCH) or clonal hematopoiesis of indeterminate potential (CHIP).<sup>42</sup> In AML, such mutations often occur very early in the process of malignant transformation.<sup>31,36,38,43,44</sup> For many other acquired mutations (that may occur later during disease development), it is unknown whether they represent reliable AML MRD markers.

Several genes mutated in germline are associated with a risk of AML *development* like *RUNX1*, *GATA2*, *CEBPA*, *DDX41*, *ANKRD26*.<sup>44</sup> Naturally, they will not correlate with disease burden, and while remaining at a variant allele frequency of 50%, will not be useful for MRD assessment. If nevertheless potential somatic mutations in these genes are used as MRD markers, we recommend excluding germline origin by DNA sequencing from germline tissue (skin biopsy, hair follicle or buccal swab). Germline origin or CHIP should be suspected and excluded if the mutation level is unchanged compared to diagnosis, despite decreased blast count.

*WT1* expression<sup>45,46</sup> (Table 2) should not be used as MRD marker, due to low sensitivity and specificity, unless no other MRD markers, including flow cytometric ones, are available in the patient. If nevertheless *WT1* is used, it should follow the validated *WT1* MRD assay<sup>45</sup> developed by ELN researchers, and preferably in PB.

In patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) the analysis of donor/recipient chimerism in PB and/or BM has been suggested as MRD

marker. The conventional detection method using fragment analysis of short tandem repeats has limited sensitivity and therefore is not recommended for MRD.<sup>47</sup> Modern techniques may allow higher sensitivity.<sup>35</sup> In addition, variant allele-specific qPCR detecting small DNA insertions or deletions may be used as a sensitive method ( $10^{-3}$ ) to detect autologous cells.<sup>48,49</sup>

Due to frequent losses or gains of certain mutations at relapse, we also recommend against the use of mutations in *FLT3-ITD*, *FLT3-TKD*, *NRAS*, *KRAS*, *IDH1*, *IDH2*, *MLL-PTD*, and expression levels of *EVII* as single markers of MRD. However, several of these not-recommended markers may have more prognostic significance when used in combination with a second MRD marker.

*Suggestions for further improvements:*

1. The combination of several markers for MRD assessment can overcome limitations of MRD assessment that are due to sub-clonal heterogeneity of AML and to CHIP. Such combination analysis will become increasingly feasible with advances in NGS MRD. For example, a patient may present with mutations in TP53, ASXL1 and PTPN11. In complete remission, the ASXL1 mutation may persist at a high VAF due to clonal hematopoiesis and cannot further be used for MRD assessment. The PTPN11 mutated clone may be successfully eradicated by chemotherapy. However, the TP53 mutated clone may persist and be part of the relapse-inducing clone. Thus, analysis of several MRD markers in one patient may increase the likelihood to identify molecular relapse.

2. In alloHSCT patients germline variants in genes associated with hematopoietic malignancy and mutations associated with CHIP should be evaluated as markers of recipient hematopoiesis to monitor MRD in the future.

**Technical requirements for molecular MRD assessment**

For reasons of sensitivity for qPCR, we recommend the use of cDNA over DNA for genes that are well expressed in AML cells (for technical details, see Suppl. Text “Technical requirements”). For new MRD markers, the expression level in AML cells should be evaluated. Detailed recommendations for MRD assays detecting *RUNX1-RUNX1T1*, *CBFB-MYH11* and *PML-RARA* have been published by the Europe Against Cancer initiative, including appropriate housekeeping genes.<sup>50,51</sup>

Each MRD analysis by PCR should be run in triplicate. Amplification in at least two of three replicates with Ct values  $\leq 40$  (at a cycling threshold of 0.1) is required to define a result as PCR positive according to EAC criteria.<sup>50</sup> As controls, we recommend including a wild type sample (normal control), at least two positive controls that cover the desired sensitivity range, and a non-target control (water control). If the positive controls are generated from plasmids, the stability of the plasmids should be monitored regularly.

After conversion of MRD from negative to positive, we recommend two specific measures to control for assay variability in the repeat samples: first, the initial sample in which molecular relapse was suspected should be included during the measurement of the repeat sample. Second, if the MRD assay is a real-time qPCR assay, standards should be included that cover the CT range of the patient samples to ensure linearity of the assay at the measured MRD level. If a negative MRD measurement is obtained, it is essential to know the sensitivity level at which it was determined. The following formula has been suggested to calculate the sensitivity of an individual real-time qPCR measurement, which can be used for absolute quantification using an external plasmid calibrator to estimate numbers of target molecules, as well as for relative quantification<sup>52,53</sup>:

$$X = [(CT_{\text{target}} - CT_{\text{ABL}})_{\text{MRD}} - (CT_{\text{target}} - CT_{\text{ABL}})_{\text{diagnosis}}] / \text{slope}$$

$$\text{Assay sensitivity} = 10^X$$

(slope = slope of the standard curve, for an assay with 100% efficiency = -3.32)

We recommend reporting the individual assay sensitivity in patients with complete molecular remission.

### **Tissue sampling and time points for MRD assessment during treatment**

The details of sampling time points and corresponding tissue source are outlined in Suppl. Table 2, and Suppl. text (under “Tissue sampling for MRD assessment”) During the treatment phase we recommend molecular MRD assessment at minimum at diagnosis, after 2 cycles of standard induction/consolidation chemotherapy and after the end of treatment in PB AND BM, as MRD in PB may provide better prognostic stratification. For patients undergoing alloHSCT, MRD should be assessed in PB and BM after the last conventional chemotherapy, but not earlier than 4 weeks before conditioning treatment. The recommended thresholds for MRD positivity are discussed



in the clinical section. The risk of relapse and overall survival probabilities for different MRD thresholds and constellations in prior studies are shown in Table 2.

**Tissue sampling and time points for MRD assessment during follow up and definition of complete molecular remission, molecular persistence at low copy number, molecular progression and molecular relapse**

In general, for patients with *PML-RARA*, *RUNX1-RUNX1T1*, *CBFB-MYH11*, mutated *NPM1* and other molecular markers, we recommend molecular MRD assessment every 3 months for 24 months after the end of treatment in BM and in PB. Monitoring beyond 2 years of follow up should be based on the relapse risk of the patient and decided individually. The prognostic impact of different MRD levels in follow-up is summarized in Table 2.

In this section and in Suppl. Table 4 we specify outcome criteria of molecular MRD based on the depth of remission at the end of the treatment phase. Patients with complete morphologic remission after treatment may be in complete molecular remission ( $CR_{MRD}$ ) or may have molecular persistence at low copy numbers. Patients in  $CR_{MRD}$  may develop molecular relapse and patients with molecular persistence may develop molecular progression. It is not known yet whether molecular relapse and molecular progression have similar clinical characteristics or outcomes. Therefore, we currently recommend distinguishing between molecular progression and molecular relapse. In the following we shortly define these terms, and in Supplementary text ("Time points for MRD assessment...") and Suppl. Table 4, the recommended frequencies of monitoring and preferable tissue source are outlined.

*Complete molecular remission ( $CR_{MRD}$ ).* To determine **complete molecular remission ( $CR_{MRD}$ )** a patient must be in complete morphologic remission (CR). We define  $CR_{MRD}$  as two successive MRD negative samples obtained within an interval of  $\geq 4$  weeks at a sensitivity level of at least 1 in 1000. Negative MRD in the presence of blasts suggests molecular loss of the particular marker.

*Molecular persistence at low copy numbers.* Molecular MRD may persist at low copy numbers, which is associated with a low risk of relapse. To label these patients we suggest the definition of **molecular persistence at low copy numbers**, which we define as MRD with low copy numbers in patients with morphologic CR ( $<100-200$

copies/ $10^4$  ABL copies corresponding to <1-2% of target to reference gene or allele burden)<sup>54,55</sup> and a copy number or relative increase < 1 log between any two positive samples collected after the end of treatment.

*Molecular progression.* We define **molecular progression** in patients with molecular persistence at low copy number as an increase of MRD copy numbers  $\geq 1 \log_{10}$  between any two positive samples.

*Molecular relapse.* Patients in complete morphologic remission who achieve molecular remission may convert to positive MRD. We define **molecular relapse** as an increase of the MRD level of  $\geq 1 \log_{10}$  between two positive samples in a patient who previously tested negative in technically adequate samples.

### **How to report molecular MRD results**

The recommended parameters that should be included in a report of molecular MRD assessments are listed in Suppl. Table 5. We recommend to report absolute copy numbers for RT-PCR results, in addition to the fold increase, to enable the clinician to make his/her own judgments.

### **Future directions**

As discussed above, the predictive power of several mutations is low or needs to be clarified. For frequently occurring point mutations, this is challenging because with current routine NGS approaches, the sensitivity of detecting these is ~1%. A higher sensitivity of detecting point mutations can be obtained with digital droplet PCR (details in Suppl. Text).<sup>56</sup> A disadvantage of ddPCR is that for each mutation a specific assay needs to be developed. Because this is time consuming and costly, this assay is especially suitable for sensitive detection of recurrent mutations like for instance in *IDH1* and *IDH2*. Recent developments including error-corrected NGS also allow for highly sensitive point mutation detection (details in Suppl. Text).<sup>57-59</sup> A significant advantage of this NGS approach is that multiple mutations can be analyzed in one single patient sample. However, this approach does require more bioinformatic processing of data. Ultimately, this approach should provide greater sensitivity and, if adopted on BM and PB, may be able to identify low level mutations in terminally mature myeloid and lymphoid cells in

PB; mutations of this nature are typically associated with clonal hematopoiesis and not leukemia.

## **Clinical paragraph on MRD**

### **MRD in clinical AML studies**

During the last 20 years, numerous single institution studies in adult and pediatric patients have established that, regardless of the detection technique (MFC, RT-PCR, or NGS) and irrespective of hematopoietic cell transplantation (HCT), presence of MRD is associated with increased relapse risk and shorter survival in AML.<sup>4,16,60</sup> Using a cut-off at a specified MRD detection threshold, the two resulting patient groups are referred to as “MRD positive” and “MRD negative”, although the latter is an oversimplification since improved outcomes do not necessarily require undetectable levels of MRD, while, inversely, a minority of MRD-negative patients will relapse as well.<sup>4,16</sup>

Two large, prospective, multicenter studies (details in Suppl. text) have identified flow cytometry-based MRD as an independent prognostic indicator in adults with AML.<sup>28,30</sup> In both studies MRD positive patients had poorer outcome in multivariate analyses.<sup>28,30</sup> In contrast to MFC, molecular assays enable MRD tracking in only a subset of patients.<sup>4</sup> Currently, validated molecular MRD targets in AML include the PML-RARA translocation in acute promyelocytic leukemia (APL), core-binding factor (CBF) translocations, and mutations in NPM1.<sup>4,16,61</sup> As an example NPM1-based MRD presented as the only independent prognostic factor for death in multivariate analysis.<sup>61</sup> Details are in Suppl. text.

Measurements of MRD using NGS techniques are under development, but are not ready for routine application outside of clinical trials.<sup>57-59</sup> Therefore, the current gold-standard measurements of MRD utilize complementary molecular and MFC-based techniques. Based on that, the following guidelines were constructed to facilitate the routine evaluation of MRD for AML patients in clinical practice, as well as for those participating in investigational trials.

### **General principles for clinical practice**

In AML, morphology-based assessments of CR can be meaningfully refined with additional information about MRD.<sup>62,63</sup> This is reflected in the 2017 ELN AML

recommendations, which now include MRD as a new response criterion (CR with/without MRD).<sup>64</sup> MRD monitoring should be considered part of the standard of care for AML patients. For molecular MRD this is limited to APL, CBF AML, and NPM1-mutated AML. For other AML patients, MRD should be assessed using MFC.<sup>4</sup> **This recommendation may change over time with emerging data for other molecular subgroups.** Failure to achieve an MRD-negative CR, or rising MRD levels during or after therapy are associated with disease relapse and inferior outcomes and should prompt consideration of changes in therapy, preferably in the setting of a controlled clinical trial.<sup>61,65</sup> **Although a rather rare event, it will have to be decided how to deal with patients who are not in morphological CR, but are in CR based on MRD assessment.** There are two concerns as to the clinical application of MRD: first, the use of cut-off levels in chemotherapy-based therapies generally reveals that different cut-off levels have different meaning in different risk groups in terms of patient outcome, and **secondly, knowledge** on the significance of MRD for patients treated with non-intensive therapies, for example DNA methyltransferase inhibitors (“hypomethylating agents”) is currently limited.<sup>66</sup> We nevertheless suggest that such patients should be monitored for MRD with the caveat that there are few data to guide interpretation of MRD results.

### **Acute promyelocytic leukemia**

In APL, the most important MRD endpoint is achievement of PCR-negativity for *PML-RARA* at the end of consolidation treatment, either with ATRA + chemotherapy-based or ATRA + arsenic trioxide-based therapies. PCR negativity at the end of consolidation is associated with a low risk of relapse and a high chance of long-term survival (see Table 2).<sup>67,68</sup> Detectable levels of *PML-RARA* by PCR during active treatment of APL should not change the treatment plan for an individual patient and it is controversial whether serial PCR measurements of *PML-RARA* during treatment are of value outside of clinical trials.<sup>65,69</sup>

At the completion of therapy, a change in status of *PML-RARa* by PCR from undetectable to detectable, as measured in either BM or PB and confirmed by a repeat sample, heralds imminent disease relapse in APL.<sup>64,67</sup>

For patients with low- and intermediate risk disease (by Sanz Score<sup>70</sup>), who are treated with an ATRA and anthracycline-based regimen, monitoring in BM at completion of induction therapy and in BM or PB every 3 month for the first two years after remission

is recommended. For patients with low/intermediate risk Sanz score who are treated with ATO and ATRA, MRD analysis should be continued until the patient is in CR<sub>MRD</sub> in BM and then should be terminated.<sup>67</sup> For patients with high-risk APL, BM or PB monitoring is recommended every 3 months after completion of therapy for at least two years. Early identification of molecular relapse could fasten clinical action, e.g. reducing bleeding complications but impact of early detection on clinical outcome has not been shown.<sup>65</sup> **Finally, the presence of a FLT3 mutation should neither change clinical management, nor demand serial monitoring.**

### **Core Binding Factor (CBF) AML**

#### *CBFB-MYH11 (Inv(16)).*

Despite the prognostic value of MRD in *CBFB-MYH11* AML in terms of relapse rate (Table 2), no effect was noted on overall survival in multivariate analysis, probably due to the relatively high response rates of inv(16) AML to salvage treatment<sup>71</sup>, and thereby no recommendation is made for a change in therapy (for more details, see Suppl. text).

MRD monitoring after two cycles of chemotherapy and after end of therapy should be performed as described in the molecular paragraph (see also Suppl. Text). It should be noted that low, stable levels of transcripts may be detectable by PCR for years after initial diagnosis without evidence of disease relapse.<sup>72</sup>

#### *RUNX1-RUNX1T1 (t(8;21))*

As with *CBFB-MYH11* positive AML, MRD assessment during the treatment phase of patients with *RUNX1-RUNX1T1* positive AML is valuable for establishment of baseline transcript levels, but, with the controversies in prognostic impact of achieving MRD negativity either in PB or in BM (Table 2)<sup>73,74</sup> (details in Suppl. Text), there is no time point or MRD threshold during the active treatment phase that should trigger a recommendation to change therapy in patients with *RUNX1-RUNX1T1* positive AML. MRD negativity at earlier time points was not prognostically-relevant in patients with *RUNX1-RUNX1T1* fusion.<sup>73,74</sup> A >3 log reduction in BM between diagnosis and the end of induction<sup>164</sup> or consolidation<sup>74</sup> was associated with significantly different relapse rates and a trend for longer OS in multivariate analysis. Patients who do not achieve > 3 log reduction in transcripts have poor outcomes but it is unclear whether this can be improved with allogeneic stem cell transplantation.

### **AML with NPM1 Mutation, with or without other, concomitant mutations**

MRD for NPM1 can be assessed by quantitative RT-PCR. The presence of measurable *NPM1* transcripts in PB after at least 2 cycles of cytotoxic chemotherapy is associated with a high risk of relapse (>80%, Table 2).<sup>61</sup> We recommend monitoring of NPM1 transcripts in BM and PB, if possible.<sup>61</sup> If *NPM1* MRD remains negative in PB but positive in BM after the end of treatment, transcripts should be closely monitored in PB and BM every 4 weeks for at least 3 months.<sup>61</sup> If an upward trajectory of MRD, as defined by a log increase in either BM or PB, is detected, consideration should be given to salvage treatment.<sup>16,55,75</sup> If a rising MRD titer is not confirmed or MRD becomes undetectable then retesting may be performed at 3 month intervals for at least the first 2 years after the end of treatment.<sup>54,55,61</sup>

### **AML with BCR-ABL1**

*BCR-ABL* positive AML was included as a provisional entity in the 2016 WHO classification.<sup>76</sup> Nearly half of the patients present with the p190 transcript, which is rarely found in CML patients.<sup>76</sup> The prognostic value of *BCR-ABL* MRD in AML is largely unknown and therefore no specific recommendations on clinical cutoffs and their prognostic impact in AML patients can be given.

### **Other molecular MRD markers**

MRD thresholds and time points for other molecular MRD markers have not been defined sufficiently to provide recommendations.<sup>16</sup> Based on current experience with fusion genes, we recommend to report the results of future MRD studies for achievement of MRD negativity in PB and BM for the time points after 2 cycles of chemotherapy and after the end of treatment.

### **AML subgroups NOT including APL, CBF AML, and AML with NPM1 mutation**

MRD for patients not included in the molecularly defined subgroups APL, CBF AML, AML with NPM1 mutation and AML with BCR-ABL1, should be measured using MFC. Having undetectable levels of MRD using MFC is associated with significantly better outcomes than having measurable disease<sup>4,52,60</sup>, even in the setting of allogeneic stem cell transplantation.<sup>28,30</sup>

### **Pre-transplant MRD**

Evidence is accumulating that the presence of MRD assessed by MFC immediately prior to alloHSCT is a strong, independent predictor of post-transplant outcomes in AML.<sup>77</sup> In a recent update, Walter et al showed that MRD status had strong predictive value both in the ablative and non-myeloablative transplant setting with MRD defined depth of response prior to transplant being the most important predictor of transplant outcome.<sup>3,78</sup> Unfortunately, conversion from MRD positivity pre-transplant to MRD negativity after myeloablative conditioning does not substantially improve relapse rate or OS.<sup>79</sup> On the other hand, in NPM1 mutated patients, MRD had prognostic impact<sup>80</sup>, while only in patients who achieved suboptimal reduction ( $<4 \log_{10}$ ) of NPM1 levels after chemotherapy, alloHSCT resulted in improved overall survival. However, no prospective studies using MRD to guide post-remission therapy are available at the time of this publication.

### **Recommendations for MRD monitoring in clinical trials**

CR<sub>MRDPOS</sub> patients have inferior outcomes even in the setting of alloHSCT representing an unmet medical need, and should be considered for enrollment in controlled clinical trials. In order to assess whether eradication or reduction of MRD using either existing or experimental therapies can a) be accomplished or b) result in improved outcomes, should be a goal of clinical trials.

All clinical trials should require molecular and/or MFC MRD at all times of evaluation of response, using the technical guidelines in this manuscript.<sup>4,29,33</sup>

### **Use of MRD as a surrogate endpoint for survival to accelerate drug approval**

Clearly MRD is used in clinical practice to guide the care of individual patients, but more data are required to establish the use of MRD as a surrogate end-point for clinical trials in AML.<sup>4</sup> If MRD negativity is established as a surrogate endpoint for survival, it is likely to be helpful for the evaluation of new drugs, possibly accelerating drug approval or, stopping development of suboptimal drugs or treatment strategies. Currently, two studies strongly suggest that MRD can be used as a surrogate for overall survival endpoints. In CBF-AML, better clinical outcomes with higher dosage of daunorubicin, was found to be associated with MRD level<sup>81</sup>, while in another study, improved overall

survival with the addition of gemtuzumab ozogamicin to standard induction therapy, correlated with MRD status.<sup>82</sup>

### **Concluding remark**

Recommendations for the MFC, molecular and clinical aspects are summarized in Table 3.

### **Acknowledgments**

The authors gratefully acknowledge Johnson & Johnson for supporting a meeting of the ELN MRD Working Party and Rudiger Hehlmann for his continuous generous support of these recommendations on behalf of the EuropeanLeukemiaNet. K. Döhner was supported in part by grants from the Else Kröner-Fresenius-Stiftung (EKFS) Germany, (project 2014\_A298), and the Sonderforschungsbereich (SFB) 1074 funded by the Deutsche Forschungsgemeinschaft (SFB 1074, project B3). M. Heuser is appointed on Heisenberg chair (DFG grant HE 5240 / 6-1). C.S. Hourigan was supported in part by the Intramural Research Program of the NHLBI, NIH. G.J. Roboz acknowledges Leukemia Fighters for support, and C. Thiede acknowledges support by Grant BMBF 031A24. P. Vyas was supported by the Oxford Biomedical Research Centre funded by the National Institutes of Health Research UK and the MRC (grants MC\_UU\_12009/11 and G1000729 ID: 94931 and MR/L008963/1). R.B. Walter is a Leukemia & Lymphoma Society Scholar in Clinical Research.

### **Authorship**

Contribution: All authors gathered and/or reviewed specific literature. G.J.S., M.H., S.F., K.D., G.J.R. and G.J.O. wrote first drafts of specific sections; all authors reviewed specific sections. G.J.S. and G.J.O. put together the specific sections and all authors, except David Grimwade, who died at an earlier stage, reviewed the final draft and approved.



Conflict-of-interest disclosure: M-C Béné received research support (Harmonemia project) from Beckman Coulter. J. Cloos received research funding from Helsinn Healthcare, Janssen Pharmaceuticals, Merus and Takeda. S. Freeman received Support from National Institute for Health Research (NIHR), CRUK and Bloodwise. T. Haferlach and W. Kern are both part owners of MLL (Munich Leukemie Laboratory). C Hourigan received research funding from Merck and Sellas. GJ Ossenkoppele provided consultancy services to Janssen and Sunesis, served on the advisory board for Novartis, Pfizer, BMS, Janssen, Sunesis, Celgene, Karyopharm, Amgen, and Seattle Genetics, and received research funding from Novartis, Janssen, Celgene, Immunogen, and Becton Dickinson. G. Roboz provided consultancy services to AbbVie, Amgen, Amphivena Therapeutics, Astex Pharmaceuticals, Array BioPharma Inc., Celgene, Clovis Oncology, CTI BioPharma, Genoptix, Immune Pharmaceuticals, Janssen Pharmaceutica, Jazz Pharmaceuticals, Juno Therapeutics, MedImmune, Novartis, Onconova Therapeutics, Orsenix, Pfizer, Roche/Genentech, Sunesis Pharmaceuticals, and received research support from Cellectis. G.J. Schuurhuis received research funding from Novartis, Janssen, Immunogen, and Becton Dickinson. C. Thiede is part CRO and CEO and owner of AgenDix GmbH, a company performing molecular diagnostics.

M. Heuser, F. Buccisano, D. Grimwade, R.K. Hills, J.L. Jorgensen, F. Lacombe, L. Maurillo, C. Preudhomme, B.A. van der Reijden, A. Venditti, P. Vyas, B.L. Wood, R.B. Walter, K. Doehner have no conflict-of-interest.

This work is in memory of David Grimwade who participated in three out of the four meetings, but died on October 16, 2016

Correspondence: Gerrit J Schuurhuis, Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, Netherlands.

E-mail: [gj.schuurhuis@vumc.nl](mailto:gj.schuurhuis@vumc.nl)

## References

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. Longo DL, ed. *N Engl J Med*. 2015;373(12):1136-1152. doi:10.1056/NEJMra1406184.
2. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N Engl J Med*. 2016;374(23):2209-2221. doi:10.1056/NEJMoa1516192.
3. Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. *Leukemia*. 2015;29(2):312-320. doi:10.1038/leu.2014.242.
4. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. *Leukemia*. April 2017. doi:10.1038/leu.2017.113.
5. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). *Blood*. 2001;97(11):3574-3580. <http://www.ncbi.nlm.nih.gov/pubmed/11369653>. Accessed May 31, 2017.
6. Langebrake C, Brinkmann I, Teigler-Schlegel A, et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. *Cytometry B Clin Cytom*. 2005;63(1):1-9. doi:10.1002/cyto.b.20037.
7. Al-Mawali A, Gillis D, Hissaria P, Lewis I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. *Am J Clin Pathol*. 2008;129(6):934-945. doi:10.1309/FY0UMAMM91VPMR2W.
8. Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a 'moving target' for detection of residual disease. *Cytom Part B Clin Cytom*. 2014;86(1):3-14. doi:10.1002/cyto.b.21134.
9. Chen X, Wood BL. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. *Blood Rev*. 2017;31(2):63-75. doi:10.1016/j.blre.2016.09.006.
10. Ho T-C, LaMere M, Stevens BM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. *Blood*. 2016;128(13):1671-1678. doi:10.1182/blood-2016-02-695312.
11. Gorczyca W, Sun Z-Y, Cronin W, Li X, Mau S, Tugulea S. Immunophenotypic pattern of myeloid populations by flow cytometry analysis. *Methods Cell Biol*. 2011;103:221-266. doi:10.1016/B978-0-12-385493-3.00010-3.
12. Olaru D, Campos L, Flandrin P, et al. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes. *Cytometry B Clin Cytom*. 2008;74(1):17-24. doi:10.1002/cyto.b.20371.
13. Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. *PLoS One*. 2014;9(9):e107587. doi:10.1371/journal.pone.0107587.
14. Bradbury C, Houlton AE, Akiki S, et al. Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. *Leukemia*. 2015;29(4):988-991. doi:10.1038/leu.2014.327.
15. van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for

standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012;26(9):1908-1975. doi:10.1038/leu.2012.120.

16. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time";? *Hematology*. 2014;2014(1):222-233. doi:10.1182/asheducation-2014.1.222.
17. Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. *Leukemia*. 2016;30(2):439-446. doi:10.1038/leu.2015.252.
18. Maurillo L, Buccisano F, Spagnoli A, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. 2007;92(ii):605-611.
19. Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. *Leukemia*. 2016;30(3):708-715. doi:10.1038/leu.2015.255.
20. Loken MR, Chu S-C, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. *Cytometry B Clin Cytom*. 2009;76(1):27-36. doi:10.1002/cyto.b.20429.
21. Delgado JA, Guillén-Grima F, Moreno C, et al. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates. *J Immunol Methods*. 2017;442:54-58. doi:10.1016/j.jim.2016.12.006.
22. Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW. Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. *Cytometry B Clin Cytom*. 2009;76(1):18-26. doi:10.1002/cyto.b.20439.
23. Aldawood AM, Kinkade Z, Rosado FG, Esan OA, Gibson LF, Vos JA. A Novel Method to Assess Bone Marrow Purity is Useful in Determining Blast Percentage by Flow Cytometry in Acute Myeloid Leukemia and Myelodysplasia. *Ann Hematol Oncol*. 2(5). <http://www.ncbi.nlm.nih.gov/pubmed/26203464>. Accessed May 11, 2017.
24. Nombela-Arrieta C, Manz M. Quantification and three-dimensional microanatomical organization of the bone marrow. *Blood Adv*. 2017;1:407-416. <http://www.bloodadvances.org/content/1/6/407%25Fssso-checked%25Dtrue%25Fsso-checked%25Dtrue%25Fsso-checked%25Dtrue%25Fsso-checked%25Dtrue%25Fsso-checked%25Dtrue%25Fsso-checked%25Dtrue%25Fsso-checked%25Dtrue%25Fsso-checked%25Dtrue%25>. Accessed May 12, 2017.
25. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. *Leukemia*. 2012;26(9):1986-2010. doi:10.1038/leu.2012.122.
26. Johansson U, Bloxham D, Couzens S, et al. Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology. *Br J Haematol*. 2014;165(4):455-488. doi:10.1111/bjh.12789.
27. Lacombe F, Bernal E, Bloxham D, et al. Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study. *Leukemia*. 2016;30(8):1769-1772. doi:10.1038/leu.2016.44.
28. Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow

- cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol.* 2013;31(31):3889-3897. doi:10.1200/JCO.2012.45.9628.
29. Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy decision-making? *Hematol Am Soc Hematol Educ Progr.* 2016;2016(1):356-365. doi:10.1182/asheducation-2016.1.356.
  30. Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. *J Clin Oncol.* 2013;31(32):4123-4131. doi:10.1200/JCO.2013.49.1753.
  31. Quek L, Otto GW, Garnett C, et al. Genetically distinct leukemic stem cells in human CD34<sup>+</sup> acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. *J Exp Med.* 2016;213(8):1513-1535. doi:10.1084/jem.20151775.
  32. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. *Blood.* 2013;122(10):1813-1821. doi:10.1182/blood-2013-06-506725.
  33. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. *Blood.* 2012;119(2):332-341. doi:10.1182/blood-2011-08-363291.
  34. Feller N, van der Pol MA, van Stijn A, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. *Leukemia.* 2004;18(8):1380-1390. doi:10.1038/sj.leu.2403405.
  35. Stahl T, Böhme MU, Kröger N, Fehse B. Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. *Exp Hematol.* 2015;43(6):462-8.e1. doi:10.1016/j.exphem.2015.02.006.
  36. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. *Nature.* 2014;506(7488):328-333. doi:10.1038/nature13038.
  37. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. *Sci Transl Med.* 2012;4(149):149ra118. doi:10.1126/scitranslmed.3004315.
  38. Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. *Proc Natl Acad Sci.* 2014;111(7):2548-2553. doi:10.1073/pnas.1324297111.
  39. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med.* 2014;20(12):1472-1478. doi:10.1038/nm.3733.
  40. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med.* 2014;371(26):2477-2487. doi:10.1056/NEJMoa1409405.
  41. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med.* 2014;371(26):2488-2498. doi:10.1056/NEJMoa1408617.
  42. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood.* 2015;126(1):9-16. doi:10.1182/blood-2015-03-631747.

43. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Cancer Cell*. 2014;25(3):379-392. doi:10.1016/j.ccr.2014.01.031.
44. Porter CC. Germ line mutations associated with leukemias. *Hematol Am Soc Hematol Educ Progr*. 2016;2016(1):302-308. doi:10.1182/asheducation-2016.1.302.
45. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. *J Clin Oncol*. 2009;27(31):5195-5201. doi:10.1200/JCO.2009.22.4865.
46. Nomdedéu JF, Hoyos M, Carricondo M, et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. *Leukemia*. 2013;27(11):2157-2164. doi:10.1038/leu.2013.111.
47. Valcárcel D, Martino R, Caballero D, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. *Bone Marrow Transplant*. 2003;31(5):387-392. doi:10.1038/sj.bmt.1703846.
48. Alizadeh M, Bernard M, Danic B, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. *Blood*. 2002;99(12):4618-4625. <http://www.ncbi.nlm.nih.gov/pubmed/12036896>. Accessed May 26, 2017.
49. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. *Leukemia*. 2003;17(3):621-629. doi:10.1038/sj.leu.2402856.
50. Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. *Leukemia*. 2003;17(12):2318-2357. doi:10.1038/sj.leu.2403135.
51. Beillard E, Pallisgaard N, van der Velden VHJ, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. *Leukemia*. 2003;17(12):2474-2486. doi:10.1038/sj.leu.2403136.
52. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for 'prime time'? *Hematol Am Soc Hematol Educ Progr*. 2014;2014(1):222-233. doi:10.1182/asheducation-2014.1.222.
53. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. *Genes Chromosomes Cancer*. 1999;26(4):355-365. <http://www.ncbi.nlm.nih.gov/pubmed/10534771>. Accessed May 12, 2017.
54. Shayegi N, Kramer M, Bornhäuser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. *Blood*. 2013;122(1):83-92. doi:10.1182/blood-2012-10-461749.
55. Krönke J, Schlenk RF, Jensen K-O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *J Clin Oncol*. 2011;29(19):2709-2716. doi:10.1200/JCO.2011.35.0371.

56. Brambati C, Galbiati S, Xue E, et al. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. *Haematologica*. 2016;101(4):e157-61. doi:10.3324/haematol.2015.135467.
57. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. *Proc Natl Acad Sci U S A*. 2012;109(36):14508-14513. doi:10.1073/pnas.1208715109.
58. Hiatt JB, Pritchard CC, Salipante SJ, O'Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. *Genome Res*. 2013;23(5):843-854. doi:10.1101/gr.147686.112.
59. Young AL, Wong TN, Hughes AEO, et al. Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing. *Leukemia*. 2015;29(7):1608-1611. doi:10.1038/leu.2015.17.
60. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. *Br J Haematol*. 2011;153(4):421-436. doi:10.1111/j.1365-2141.2011.08595.x.
61. Ivey A, Hills RK, Simpson MA, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. *N Engl J Med*. 2016;374(5):422-433. doi:10.1056/NEJMoa1507471.
62. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. *Blood*. 2012;120(8):1581-1588. doi:10.1182/blood-2012-02-408336.
63. Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. *J Clin Oncol*. 2012;30(29):3625-3632. doi:10.1200/JCO.2011.41.5323.
64. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447. doi:10.1182/blood-2016-08-733196.
65. Grimwade D, Jovanovic J V., Hills RK. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? *Best Pract Res Clin Haematol*. 2014;27(1):53-61. doi:10.1016/j.beha.2014.04.002.
66. Ragon BK, Daver N, Garcia-Manero G, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. *Am J Hematol*. 2017;92(9):845-850. doi:10.1002/ajh.24782.
67. Grimwade D, Jovanovic J V, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. *J Clin Oncol*. 2009;27(22):3650-3658. doi:10.1200/JCO.2008.20.1533.
68. Platzbecker U, Avvisati G, Cicconi L, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. *J Clin Oncol*. 2017;35(6):605-612. doi:10.1200/JCO.2016.67.1982.
69. Freeman SD, Jovanovic J V, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. *Semin Oncol*. 2008;35(4):388-400. doi:10.1053/j.seminoncol.2008.04.009.
70. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of

- nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. *Blood*. 2000;96(4):1247-1253. <http://www.ncbi.nlm.nih.gov/pubmed/10942364>. Accessed July 4, 2017.
71. Yin J a L, O'Brien M a, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. *Blood*. 2012;120(14):2826-2835. doi:10.1182/blood-2012-06-435669.
  72. Yin JAL, Frost L. Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia. *Curr Oncol Rep*. 2003;5(5):399-404. <http://www.ncbi.nlm.nih.gov/pubmed/12895392>. Accessed November 14, 2017.
  73. Agrawal M, Corbacioglu A, Paschka P, Weber D, Gaidzik VI, Jahn N et al. Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AML SG). *Blood*. 2016.
  74. Willekens C, Blanchet O, Renneville A, et al. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. *Haematologica*. 2016;101(3):328-335. doi:10.3324/haematol.2015.131946.
  75. Shayegi N, Kramer M, Bornhäuser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. *Blood*. 2013;122(1):83-92. doi:10.1182/blood-2012-10-461749.
  76. Neuendorff NR, Burmeister T, Dörken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. *Ann Hematol*. 2016;95(8):1211-1221. doi:10.1007/s00277-016-2721-z.
  77. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. *Haematologica*. 2017;102(5):865-873. doi:10.3324/haematol.2016.159343.
  78. Araki D, Wood BL, Othus M, et al. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? *J Clin Oncol*. 2016;34(4):329-336. doi:10.1200/JCO.2015.63.3826.
  79. Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. *Leukemia*. 2016;30(7):1456-1464. doi:10.1038/leu.2016.46.
  80. Balsat M, Renneville A, Thomas X, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. *J Clin Oncol*. 2017;35(2):185-193. doi:10.1200/JCO.2016.67.1875.
  81. Prebet T, Bertoli S, Delaunay J, et al. Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. *Haematologica*. 2014;99(10):e185-7. doi:10.3324/haematol.2014.109827.
  82. Lambert J, Lambert J, Nibourel O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. *Oncotarget*. 2014;5(15):6280-6288. doi:10.18632/oncotarget.2196.

83. San Miguel JF, Martínez a, Macedo a, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. *Blood*. 1997;90(6):2465-2470. <http://www.ncbi.nlm.nih.gov/pubmed/9310499>.
84. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. *Blood*. 2000;96(12):3948-3952. <http://www.ncbi.nlm.nih.gov/pubmed/11090082>.
85. San Miguel JF. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. *Blood*. 2001;98(6):1746-1751. doi:10.1182/blood.V98.6.1746.
86. Sievers EL, Lange BJ, Alonzo T a, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. *Blood*. 2003;101(9):3398-3406. doi:10.1182/blood-2002-10-3064.
87. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. *Blood*. 2004;104(10):3078-3085.
88. Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. *Haematologica*. 2004;89(5):528-540. <http://www.ncbi.nlm.nih.gov/pubmed/15136215>. Accessed July 7, 2017.
89. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. *Leukemia*. 2006;20(10):1783-1789. doi:10.1038/sj.leu.2404313.
90. Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. *J Clin Oncol*. 2006;24(22):3686-3692. doi:10.1200/JCO.2005.05.4312.
91. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. *J Clin Oncol*. 2008;26(30):4944-4951. doi:10.1200/JCO.2007.15.9814.
92. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. *Am J Clin Pathol*. 2009;131(1):16-26. doi:10.1309/AJCP5TSD3DZXFLCX.
93. van der Velden VHJ, van der Sluijs-Geling a, Gibson BES, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. *Leuk Off J Leuk Soc Am Leuk Res Fund, UK*. 2010;24(9):1599-1606. doi:10.1038/leu.2010.153.
94. Buccisano F, Maurillo L, Piciocchi A, et al. Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. *Ann Hematol*. 2015;94(8):1319-1326. doi:10.1007/s00277-015-2364-5.
95. Vidriales M-B, Pérez-López E, Pegenaute C, et al. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. *Leuk Res*. 2016;40:1-9.



- doi:10.1016/j.leukres.2015.10.002.
96. Tierens A, Bjorklund E, Siitonen S, Vibeke Marquart H, Wulff-Juergensen G, Pelliniemi T-T, Forestier E, Hasle H, Jahnukainen K, Lausen B, Jonsson OG, Palle J, Zeller B, Fogelstrand L AJ. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. *BrJHaematol*. 2017. doi:10.1111/bjh.14093.
  97. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. *Lancet Oncol*. 2010;11(6):543-552. doi:10.1016/S1470-2045(10)70090-5.
  98. Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. *Leukemia*. 2015;29(1):137-144. doi:10.1038/leu.2014.173.
  99. Krönke J, Schlenk RF, Jensen K-O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *J Clin Oncol*. 2011;29(19):2709-2716. doi:10.1200/JCO.2011.35.0371.

**Table 1 . Key studies on the prognostic value of MRD by Multi Parameter Flow Cytometry\***

Publication	Multi Center Yes/No	Study population Adult/Children	% LAIP	Number of Patients	MRD measurement following	Cut-off MRD level			Univariate analysis significant for	Multivariate analysis significant for	Study details
						I	C	postTx			
San Miguel et al <sup>83</sup>	N	A	46%	53	I, C	<0.05%	0.2%		RFS, OS	RFS	
Venditti et al <sup>84</sup>	Y	A	70%	56	I, C	0.045%	0.035%		I:- C:RFS, OS	I:- C:RFS, OS	
San Miguel et al <sup>85</sup>		A	75%	126	I	<0.01%, 0.01-0.1% 0.1-1% >1%	- - - -		RFS, OS	RFS	MRD>1%: 3 yr RR: 85% MRD 0.1-1.0%: 3 yr RR:45% MRD 0.01-0.1%: 3yr RR 14% MRD <0.01%: 3yr RR: 0%
Sievers et al <sup>86</sup>	Y	C	?	252	I <sub>1</sub>	0.5%			RFS, OS	RFS, OS	3 yr OS 69% (MRD neg) vs 41%(MRD pos)
Kern et al <sup>87</sup>	Y	A	100%	106	Day 16	Log difference 2.11			CR, EFS, RFS, OS	EFS, RFS	
Kern et al <sup>88</sup>	N	A	100%	62	I, C	Log difference 2.11	Log difference 2.53		I: RFS C: RFS, OS	I: RFS C: RFS	
Feller et al <sup>34</sup>	N	A	100%	72	I <sub>1</sub> , I <sub>2</sub> , C, PBSCT	I <sub>1</sub> :1% I <sub>2</sub> :0.14%	0.11%	0.13%	I <sub>1</sub> , I <sub>2</sub> , C, PBSCT; RFS, OS	I <sub>1</sub> , I <sub>2</sub> , C, PBSCT; RFS, OS	
Buccisano et al <sup>89</sup>	A	A	89%	100	I, C	0.035%	0.035%		I and C: RR, RFS, OS	I:- C: RR, RFS, OS	5 yr RFS 72% (MRD neg) vs 11%(MRD pos)
Langebrake et al <sup>90</sup>	Y	A, C	?	150	Day 15, I, I <sub>2</sub> , C	0.1-2%	0.1-1.3%		Day 15, I; RFS	-	MRD similar EFS as traditional Risk factors
Maurillo et al <sup>91</sup>	Y	A	?	142	I, C	0.035%	0.035%		I and C; RFS, OS	I and C; RFS, OS	5 yrs RR 60%(MRD pos)vs 16% 9MRD neg)
Al Mawali et al <sup>92</sup>	N	A	94%	54	I, C	0.15%	0.15%		I: RFS, OS C: RFS, OS	I: RFS, OS C:-	
Van der Velden et al <sup>93</sup>	Y	C	?	94	I <sub>1</sub> , I <sub>2</sub> , C, end of Tx	<0.1% 0.1-0.5% >0.5%			I <sub>1</sub> : RFS, OS	I <sub>1</sub> : RFS, OS	3yr RFS 64%(MRD pos) vs 14% (MRD neg )
Loken et al <sup>62</sup>	Y	C	100%	188	I <sub>1</sub> , I <sub>2</sub> , end of Tx	>0%, 0-1%			I <sub>1</sub> : OS, RFS I <sub>2</sub> : RFS, OS	I <sub>1</sub> : OS, RFS I <sub>2</sub> : RFS, RR	RR at 3yrs 60%vs 29%
Inaba et al <sup>63</sup>	Y	C	?	203	I <sub>1</sub> , I <sub>2</sub> , end of Tx	<0.1%, 0.1-1% >1%			I <sub>1</sub> : EFS, RFS I <sub>2</sub> : EFS, RFS	I <sub>1</sub> : EFS, RFS I <sub>2</sub> : EFS, RFS	Morphological assessment has limited value in comparison to flowcytometry
Terwijn et al <sup>28</sup>	Y	A	89%	517	I <sub>1</sub> , I <sub>2</sub> ,	<0.1%	<0.1%		I <sub>1</sub> : RFS, OS I <sub>2</sub> : RFS, OS	I <sub>1</sub> : RFS, OS I <sub>2</sub> : RFS, OS	Cut off points between 0.05-0.8 are all significant
Freeman et al <sup>30</sup>	Y	A	93%	427	I <sub>1</sub> , I <sub>2</sub> ,	<0.1%	<0.1%			I <sub>1</sub> : RFS, OS I <sub>2</sub> : RFS, OS	3yr OS 38%(MRD pos) vs 18% (MRD neg) after Cycle 2
Walter et al <sup>32</sup>	N	A, C	100%	253	Pre Tx	<0.1%			DFS OS		MRD predictive in CR1 and CR2

<b>Buccisano et al</b> <sup>94</sup>	Y	A	?	210	I,C	0.035%	0.035%	I,C:DFS, OS	I,C: DFD, OS	MRD negativity gives 5yr DFS : 57vs13% in elderly AML
<b>Araki et al</b> <sup>78</sup>	N	A	100%	359	Pre Tx	0.1%			OS,PFS,RFS	3yr RR 67% (MRD pos) vs 22%(MRD neg)
<b>Vidriales et al</b> <sup>95</sup>	Y	A	100%	306	At the time of morphological CR	<0.01%, 0.01-0.1% >0.1%		RFS	RFS	Multivariate analysis revealed MRD, age and cytogenetics as independent variables. Cytogenetics and MRD are complementary in a scoring system
<b>Tierens et al</b> <sup>96</sup>	Y	C	78%	101	Day 15, pre C	0.1%	0.1%	Day 15:EFS,OS Pre C: EFS,OS	Day 15:EFS,OS Pre C:EFS,OS	EFS at 5 yrs 65%( MRD neg) vs 22%(MRD pos)
<b>Rubnitz et al</b> <sup>97</sup>	Y	C (1-21yrs)	?	216	I <sub>1</sub> , I <sub>2</sub>	<0.1%, 0.1-1% >1%	- -	EFS OS	I <sub>1</sub> , I <sub>2</sub> :EFS I <sub>1</sub> , I <sub>2</sub> :OS	I <sub>1</sub> :CIR at 3yrs 38.6 %for MRD pos and 16.9% for MTD neg I <sub>2</sub> :56.3% vs 16.7%
<b>Walter et al</b> <sup>98</sup>	N	A	100%	241	Pre TX	0.1%		DFS, OS, relapse	DFS,OS,relapse	Negative impact of MRD on post transplant MRD is similar after NMA and MA conditioning

\*Adapted from Ossenkoppele, G., & Schuurhuis, G. J.<sup>29</sup>

?, not known; A, adult; C, consolidation; Ch, children; CIR, cumulative incidence of relapse;DFS, disease-free survival; diff., difference; I, induction treatment; I<sub>1</sub>, induction cycle 1; I<sub>2</sub>, induction cycle 2C; N, no;LAIP, Leukemia associated phenotype; MA,myeloablative; NMA, non myelo-ablative,PBSCT, peripheral blood stem cell transplantation; Pop., population; pts, patients; OS, overall survival, Ref., reference; RR, relapse risk; Tx, transplantation; Y, yes.

**Table 2. Prognostic thresholds for molecular MRD markers in AML patients who are in complete morphologic remission**

Gene	Number of patients	Time point	PB vs. BM	cDNA vs. DNA	Favorable prognostic cutoff (proportion of patients)	Associated risk	Sensitivity of the assay	Reference
<b>NPM1</b>	194	After 2 cycles of chemotherapy	PB	cDNA	Negative (84.5%)	3-year CIR 30% (vs 82% if positive), 3-year OS 75% (vs 24% if positive)	$10^{-5}$ (range, $10^{-3.7}$ to $10^{-7.1}$ )	Ivey et al. <sup>61</sup>
<b>NPM1</b>	137	After 2 cycles of chemotherapy	BM	cDNA	Negative (19%)	4-year CIR 6.4% (vs 53% if positive), 4-year OS 90% (vs. 56% if positive)	$10^{-5}$ to $10^{-6}$	Krönke et al. <sup>99</sup>
<b>NPM1</b>	82	After 2 cycles of chemotherapy	BM	cDNA	Negative (26%)	3-year OS 84% (vs 76% if NPM1/ABL $\leq 1\%$ vs 47% if NPM1/ABL $> 1\%$ )		Shayegi et al. <sup>75</sup>
<b>NPM1</b>	194	At end of treatment	PB	cDNA	Negative (92%)	3-year OS 80% (vs not estimable if positive)	$10^{-5}$ (range, $10^{-3.7}$ to $10^{-7.1}$ )	Ivey et al. <sup>61</sup>
<b>NPM1</b>	131 (for PB)	After 1 or 2 induction cycles	PB	cDNA	$\geq 4\log_{10}$ reduction (55%)	3-year CIR 20.5% (vs 65.8% if $< 4\log_{10}$ reduction); 3-year OS 91-93% (vs 40.8% if $< 4\log_{10}$ reduction)	0.01%	Balsat et al. <sup>80</sup>
<b>NPM1</b>	129	At end of treatment	BM	cDNA	Negative (48%)	4-year CIR 15.7% (vs 66.5% if positive), 4-year OS 80% (vs. 44% if positive)	$10^{-5}$ to $10^{-6}$	Krönke et al. <sup>99</sup>

<b>NPM1</b>	80	At end of treatment	BM	cDNA	Negative (49%)	1-year CIR 37% (vs 63% if NPM1/ABL ≤1% vs 85% if NPM1/ABL >1%); 2-year OS 82% (vs 61% if NPM1/ABL ≤1% vs 45% if NPM1/ABL >1%)	10 <sup>-5</sup>	Shayegi et al. <sup>75</sup>
<b>NPM1</b>	136	In follow-up	BM	cDNA	< 200 copies (68% of patients completing chemotherapy)	No relapses occurred	10 <sup>-5</sup> to 10 <sup>-6</sup>	Krönke et al. <sup>99</sup>
<b>RUNX1-RUNX1T1</b>	94	At end of treatment	PB	cDNA	Negative (70%)	4-year CIR 23.6% (vs 50.9% if positive), 4-year OS 96% (vs 63.6% if positive)	10 <sup>-5</sup>	Willekens et al. <sup>74</sup>
<b>RUNX1-RUNX1T1</b>	120	At end of treatment	BM	cDNA	Negative (49%)	4-year EFS 81% (vs 61% if positive), 4-year OS 93% (vs 67% if positive)	10 <sup>-6</sup>	Agrawal et al. <sup>73</sup>
	94	At end of treatment	BM	cDNA	Negative (30%)	4-year CIR 28.2% (vs 33.8% if positive), 4-year OS 86.4% (vs 87.7% if positive, n.s.)	10 <sup>-5</sup>	Willekens et al. <sup>74</sup>
<b>RUNX1-RUNX1T1</b>	163	In follow-up	PB	cDNA	<100 copies/10 <sup>5</sup> ABL copies (85%)	5-year CIR 7% (vs 100% if ≥100), 5-year OS 95% (vs 59% if ≥100)	10 <sup>-5</sup>	Yin et al. <sup>71</sup>
<b>RUNX1-</b>	163	In follow-up	BM	cDNA	<500	5-year CIR 7% (vs	10 <sup>-5</sup>	Yin et al. <sup>71</sup>

<b>RUNX1T1</b>					copies/ $10^5$ ABL copies (83.5%)	100% if $\geq 500$ , 5-year OS 94% (vs 57% if $\geq 500$ )		
<b>CBFB- MYH11</b>	115	At end of treatment	PB	cDNA	<10 copies/ $10^5$ ABL copies (80%)	5-year CIR 36% (vs 78% if $\geq 10$ )	$10^5$	Yin et al. <sup>71</sup>
<b>CBFB- MYH11</b>	115	In follow up	PB	cDNA	<10 copies/ $10^5$ ABL copies (69%)	5-year CIR 7% (vs 97% if $\geq 10$ ), 5-year OS 91% (vs 57% if $\geq 10$ )	$10^5$	Yin et al. <sup>71</sup>
<b>CBFB- MYH11</b>	115	In follow up	BM	cDNA	<50 copies/ $10^5$ ABL copies (73%)	5-year CIR 10% (vs 100% if $\geq 50$ ), 5-year OS 100% (vs 25% if $\geq 50$ )	$10^5$	Yin et al. <sup>71</sup>
<b>PML- RARA</b>	301	At end of treatment (ATRA+anthracy cline based)	BM	cDNA	Negative (95%)	3-year CIR 11% (vs 34% if positive)	At least $10^3$	Grimwade et al. <sup>67</sup>
<b>PML- RARA</b>	115	At end of treatment (ATO+ATRA, low and interm. risk APL)	BM	cDNA	Negative (100%)	4.2-year CIR 1.9%	n.d.	Platzbecker et al. <sup>68</sup>
<b>WT1</b>	129	After induction	PB or BM	cDNA	$\geq 2$ log reduction in the same tissue (PB or BM) (62%)	5-year CIR 40% (vs 75% if <2 log)	$10^4$	Cilloni et al. <sup>45</sup>
<b>WT1</b>	584	At end of treatment	BM	cDNA	<10 copies (32%)	3-year CIR 25% (vs 45% if 10-100 copies vs 72 of >100)	$10^4$	Nomdedeu et al. <sup>46</sup>

copies), 3-year OS  
72% (vs 59% if 10-  
100 copies vs 30% if  
>100 copies)

Abbreviations: PB, peripheral blood; BM, bone marrow; CIR, cumulative incidence of relapse; OS, overall survival;  
n.s., not significant, ATO, arsenic trioxide; ATRA, all-trans retinoic acid.

**Table 3. ELN recommendations for MRD assessment**

Flow cytometry	Recommendations
1.	<p>Use the following markers in a MRD panel:</p> <p>CD7, CD11b, CD13, CD15, CD19, CD33, CD34, CD45, CD56, CD117, HLA-DR (backbone: CD45,CD34,CD117, CD13,CD33,FSC/SSC)</p> <p>If necessary, add a “monocytic tube” containing: CD64/CD11b/CD14/CD4/CD34/HLA-DR/CD33/CD45.</p>
2.	<p>Integrate the classic LAIP approach with the different-from-normal (DfN) approach. To trace all aberrancies (at and beyond diagnosis, including newly formed post-diagnosis aberrancies) apply a full panel both at diagnosis and at follow up.</p>
3.	<p>Aspirate 5 - 10 mL BM and use the first pull for MRD assessment. At present PB, with its lower MRD content, should not be used for MRD assessment.</p> <p>Pull as low as desirable BM volume since contamination with PB increases with BM volume</p>
4.	<p>Estimate the contamination with PB, especially when a first pool of BM was impossible.</p>
5.	<p>Use 500,000 to one million white blood cells, use the best aberrancy available and relate it to CD45+ white blood cells.</p>



6.	To define “MRD-negative” and “MRD-positive” patient group, a cut-off of 0.1% is recommended.
7.	If true MRD <0.1% is found, report this as “MRD-positive <0.1%, may be consistent with residual leukemia”. If applicable the comment “this level has not been clinically validated” should be added.
8.	In a multicenter setting transport and storage of full BM at room temperature for a period of 3 days is acceptable.
9.	<i>Single center</i> studies with no extensive experience on MFC MRD are strongly discouraged

Molecular Biology	Recommendations
1.	Molecular MRD analysis is indifferent to the anticoagulant used during cell sampling and thus both heparin or EDTA can be used as anticoagulant.
2.	Aspirate 5 - 10 mL BM and use the first pull for molecular MRD assessment.
3.	<i>WT1</i> expression should not be used as MRD marker, unless no other MRD marker is available in the patient.
4.	Do not use of mutations in <i>FLT3-ITD</i> , <i>FLT3-TKD</i> , <i>NRAS</i> , <i>KRAS</i> , <i>DNMT3A</i> ,



	<i>ASXL1</i> , <i>IDH1</i> , <i>IDH2</i> , <i>MLL-PTD</i> and expression levels of <i>EVI1</i> as single MRD markers. However, these markers may be useful when used in combination with a second MRD marker.
5.	We define <b>molecular progression</b> in patients with molecular persistence as an increase of MRD copy numbers $\geq 1 \log_{10}$ between any two positive samples. Absolute copy numbers should be reported in addition to the fold increase to enable the clinician to make his/her own judgments.
6.	We define <b>molecular relapse</b> as an increase of the MRD level of $\geq 1 \log_{10}$ between two positive samples in a patient who was previously tested negative.  The conversion of negative to positive MRD in PB or BM should be confirmed 4 weeks after the initial sample collection in a second sample from both BM and PB. If MRD increases in the follow up samples $\geq 1 \log_{10}$ , molecular relapse should be diagnosed.

Clinical	Recommendations
1.	Refine morphology-based CR by assessment of MRD, because CR MRD <sub>neg</sub> is a new response criterium according to the AML ELN recommendation 2017.  Use MRD to refine risk assessment prior to consolidation treatment,

	the post-induction time point closest to consolidation treatment is recommended.
2.	<p>MRD monitoring should be considered part of the standard of care for AML patients.</p> <p>Monitoring beyond 2 years of follow up should be based on the relapse risk of the patient and decided individually.</p> <p>Patients with mutant <i>NPM1</i>, <i>RUNX1-RUNX1T1</i>, <i>CBFB-MYH11</i> or <i>PML-RARA</i> should have molecular assessment of residual disease at informative clinical time points.</p>
3.	Not to assess molecular MRD in subtypes other than APL, CBF AML, and NPM1-mutated AML
4.	<p>For AML patients NOT included in the molecularly defined subgroups above, MRD should be assessed using MFC</p> <p>During the treatment phase we recommend molecular MRD assessment at minimum at diagnosis, after 2 cycles of standard induction/consolidation chemotherapy and after the end of treatment in PB AND BM.</p> <p>During follow up of patients with <i>PML-RARA</i>, <i>RUNX1-RUNX1T1</i>, <i>CBFB-MYH11</i>, mutated <i>NPM1</i> and other molecular markers we recommend molecular MRD assessment every 3 months for 24 months after the end of treatment in BM and in PB. Alternatively, PB may be assessed</p>

	every 4-6 weeks.
5.	Failure to achieve an MRD-negative CR, or rising MRD levels during or after therapy are associated with disease relapse and inferior outcomes and should prompt consideration of changes in therapy
6.	In APL, the most important MRD endpoint is achievement of PCR-negativity for <i>PML-RARA</i> at the end of consolidation treatment  For patients with PML-RARA fusion and low/intermediate risk Sanz score who are treated with ATO and ATRA, MRD analysis should be continued until the patient is in <b>CR<sub>MRD</sub></b> in BM and then should be terminated.
7.	Detectable levels of <i>PML-RARA</i> by PCR during active treatment of APL should not change the treatment plan for an individual patient
8.	A change in status of PML-RARa by PCR from undetectable to detectable, and confirmed by a repeat sample, should be regarded as an imminent disease relapse in APL
9.	Patients with CBF AML should have an initial assessment of MRD after two cycles of chemotherapy, followed by serial measurements every 3 months for at least the first 2 years after the end of treatment
10.	MRD should be assessed pre-transplant.
11.	MRD should be performed post-transplant
12.	All clinical trials should require molecular and/or MFC assessment of

	MRD at all times of evaluation of response



**Figure 1A. MFC MRD scenarios.**

<b>Sample Quality</b>	
<b>Viability</b> (sample age)	Acceptable / Poor (eg > 96 hours)
<b>Total cells acquired</b> (for reported LAIP tube)	X
<b>CD45+ cells acquired</b> (for reported LAIP tube)	X
<b>Hemodilute</b>	Yes / no / not assessed
<b>Blast/progenitor %</b>	X% Gated by (highlight below gate selected for blast %) CD34 and/or CD117 CD45/SSC Monocytic markers Other (specify)
<b>Sample Quality is</b> Adequate / Borderline / Inadequate	
<b>MFC MRD</b>	
<b>Diagnostic LAIP</b>	Yes or No (no LAIP found in diagnostic sample) or No adequate diagnostic sample
<b>LAIP / DfN used for MFC MRD</b>	Diagnostic x as % of blasts at diagnosis (coverage) or Follow-up (no diagnostic information) or Change (new LAIP compared to previous diagnosis / follow-up)
<b>LAIP / DfN reported</b>	eg 56+117+34+33+
<b>Specificity</b> (detection threshold)	= eg 0.02% (maximum % control BM cells in LAIP region)

MFC MRD	X% MFC MRD	X% blasts (or X% myeloblasts)
<b>CONCLUSION</b>	<p><b>MFC MRD not possible</b>  <b>or MFC MRD positive</b>  <b>or MFC MRD negative</b> (can add 'no MFC MRD identified' if no MRD events)  <b>or MFC MRD detectable and quantifiable but uncertain significance</b>  (eg &lt;0.1% or a ?treatment related or ?pre-leukemic DfN LAIP)</p>	

**Figure 1B. MFC MRD scenario.**

Example of MFC MRD report template